160 - Addressing Impurities and By-Products in Pharmaceutical Process Development (S11E10)

Welcome to the Deep Dive. Today, we're tackling
something really, really critical in how your
medications get made safely. We're talking about
how scientists find, control, and manage those
unwanted extras, impurities, and byproducts that
can show up when making drugs. It's all about
making sure the medicine is pure and safe. We'll
be exploring the strategies, the analysis, the
whole detective work behind it. Exactly. And
our mission, you could say, is to distill the
key ideas from various sources. We're looking
at development guides, regulatory thinking, especially
around tricky substances, and even some real
-world case studies. The goal is to give everyone
a clear picture of this complex area, but without
getting totally bogged down in the jargon. OK,
let's start at the beginning then. When a drug
first shows promise, the amounts are tiny, right?
Lab scale. But moving towards clinical trials,
towards patients, that means scaling up. Big
time. from milligrams, maybe, to kilograms. And
our sources point out this scale -up step, that's
often where the impurity challenges really surface.
Yeah, it's interesting, isn't it? Making more
of something isn't always straightforward. Bigger
batches can actually open the door for new side
reactions. It might seem a bit counterintuitive.
Think about baking a giant cake versus a cupcake.
Heat distribution changes. Ingredients interact
differently over longer times. Process chemists
are the experts here. Their job is designing
synthetic routes that aren't just scalable, but
also cleaner by design. They try to avoid toxic
stuff and maximize the good product. And there's
one type of impurity that gets a lot of focus.
You sometimes hear about them, genotoxic impurities
or GTIs. These could be things like alkylating
agents, maybe nitrosamines. The worry is their
potential to damage DNA. That's the core concern.
They can interact with our DNA, which is obviously
not good. And if you look at the wider regulatory
landscape, like the thinking behind the ICH guidelines,
there's a huge emphasis on assessing and controlling
these specific DNA reactive impurities. These
guidelines are basically the international rulebook
for drug safety. M7, for instance, really drools
down on how to handle these potential mutagens.
So drug developers, right from the start, they
need to figure out if their drugs' specific chemistry
poses any unique risks, like forming GTIs. And
they need a solid plan for managing those risks
all the way through development and manufacturing,
which is exactly why you need those sharp analytical
techniques early on just to even spot these potential
problems. Okay, so impurities can pop up, especially
when you make more stuff. But what are the actual
strategies? How do scientists try to keep them
low from the get -go? It can't just be about
cleaning up afterwards, right? There must be
proactive approaches. Oh, absolutely. A big part
of it is cleverly modifying the chemical process
itself, designing it so it naturally produces
fewer byproducts. We saw a great example in one
case study on dichromate nip synthesis. They
actually tweaked the synthetic route, the steps
involved. And by doing that, they significantly
cut down on a specific unwanted impurity, abyssumide.
It's about smarter chemistry design up front.
Right, so it's less like mopping up spills and
more like designing better plumbing so it doesn't
leak in the first place. That's a perfect analogy.
Process research is exactly that, developing
synthesis methods that work well at large scale
and address potential problems, like impurity
formation, before they happen. Another source
mentioned a synthesis for azacromenone and azacromylamine.
The initial way they tried making it hit bottlenecks,
which could have led to more impurities. So the
solution wasn't just tweaking, it was devising
a whole new way to assemble the molecule, a different
strategy altogether. And often, especially later
in development, you see a shift away from really
complex or let's say inefficient chemical steps.
Things like multiple oxidation state changes.
The idea to streamline the process, make it more
efficient, and crucially, less likely to generate
unwanted side products. That Decomitinib example
also sort of touched on this optimization aspect.
And it sounds like even something seemingly basic,
like just the recipe, how much of each chemical
you add, the stoichiometry that plays a big role
too. A massive role. One paper we looked at detailed
the synthesis of a particular intermediate chemical.
It showed how critical it is to control the exact
amounts, the stoichiometry. If you don't, you
risk getting over -reacted products or under
-reacted ones. Both are impurities. Think about
baking again. Too much sugar. Different cake.
Not enough flour. It falls apart. Same idea in
chemistry. An imbalance leads to side reactions,
leads to impurities. Okay, so scientists are
trying hard to prevent impurities during synthesis,
but inevitably, some might still be there, maybe
in tiny amounts. That's where the analytical
chemists come in, the detectives. How do they
actually find and measure these trace -unwanted
things? Yes, this stage is absolutely vital.
The sources really stress using a strategic,
chemistry -informed approach. It's not random
testing. You use a whole toolkit of analytical
techniques, often step -by -step, like forensic
tools at a crime scene. Each tells you something
different. HPLC, mass spectrometry, NMR. And
these techniques help differentiate. They help
figure out which impurities are, let's say, relevant.
Maybe they're above a certain threshold or known
to be risky, and which are just potential impurities,
maybe detectable, but at such low levels they
aren't likely to cause harm. So a potential impurity
might just be a tiny blip, well below any level
of concern, but a relevant one. That needs careful
monitoring and control based on safety data and
regulatory limits. So it's not just about finding
every single other molecule, but really focusing
on what could actually matter for safety or effectiveness.
Precisely. And having that deep knowledge, knowing
what impurities could form, also helps make other
important decisions, like choosing the right
kind of packaging or figuring out the best long
-term storage conditions. You need to know if
an impurity might increase over time, affecting
the drug's stability or potency. We mentioned
genotoxic impurities earlier, GTIs, and the sources
really underscore why they're such a big deal.
Can we explore that a bit more? What makes them
particularly concerning? The fundamental issue,
as we touched on, is their potential to damage
DNA. And DNA damage unfortunately is linked to
cancer risk. That's the main concern. So regulatory
guidelines, the thinking reflected in ICH standards,
puts a very, very strong focus on these. For
the really potent ones, sometimes called the
cohort of concern, things like aflatoxin -like
structures and nitroso compounds, alkalizoxy
compounds, the acceptable levels are incredibly
low. We're talking parts per million or even
less. The acceptable daily intake is likely to
be vanishingly small. Ideally, you want zero
presence, especially since they usually offer
no benefit to making the drug anyway. That makes
total sense. Why have something potentially harmful
around if it's not even necessary for the process?
Exactly right. Now, there can be very rare situations,
maybe for a serious disease with few or no other
treatments. A covert mutagenic impurity might
be, technically, unavoidable in the synthesis.
In those specific rare cases, the principle is,
as low as reasonably practicable. Alarp. This
means you have to prove you've done absolutely
everything technically feasible to minogiz it
even if you can't eliminate it. It requires a
huge amount of scientific justification, data,
and usually close discussion with the regulatory
agencies. It becomes a very careful risk -benefit
calculation. Now, listening to all this identifying,
preventing, detecting, controlling it feels like
there must be an enormous amount of paperwork
of record keeping involved. Our sources didn't
explicitly detail process documentation, but
it seems like a really robust system for tracking
everything is just essential, a kind of paper
trail for the medicine. You've absolutely nailed
a critical point there. While the specific term
process documentation might not have been highlighted
in the snippets we looked at, the whole framework
of good manufacturing practices, GMP, definitely
implies it. It underpins everything. GMP is the
bedrock ensuring quality and consistency in all
pharmaceuticals. And a core part of GMP is traceability.
Being able to know exactly how every batch was
made, what went into it, what checks were done
at every single step that's fundamental for managing
impurities. It lets manufacturers and regulators
trace back any potential issue to its source
and make sure corrective actions are taken effectively.
Right, so it's about having that clear, auditable
history. Proof that every stage was controlled
properly to minimize contamination and ensure
the final product is pure. Precisely. GMP requires
very tightly controlled manufacturing conditions,
validated processes, everything designed to prevent
unintended substances getting in or forming.
And this ties directly back to that ultimate
goal we keep mentioning. Making sure the medicine
that gets to the patient is safe, pure, and does
what it's supposed to do. Effective. It really
does all circle back to the patient in the end,
doesn't it? All these complex strategies, the
detailed chemistry, the high -tech analysis,
the strict rules. Ultimately, it's all geared
towards ensuring that when someone takes a medication,
they can trust it. Trust it to help, not harm.
That really is the fundamental ethical principle
driving all this. Yeah. The absolute goal is
delivering pharmaceuticals that not only work
therapeutically, but meet the very highest standards
of quality and safety for the people who rely
on them. OK, so to kind of wrap up our deep dive
today, we've journeyed through this really crucial
world of impurity management and making medicines.
We've seen how vital early identification and
proactive control are, how important it is to
optimize the chemical synthesis itself to avoid
making byproducts. We've touched on the indispensable
role of sophisticated analytical techniques for
finding and understanding impurities, even tiny
traces. And we highlighted those specific worries
around genotoxic impurities and the really strict
controls needed there. all under that umbrella
of good manufacturing practices and ultimately
patient safety. And thinking ahead, maybe a final
thought for our listeners. As drug molecules
get more complex and manufacturing itself evolves,
how much more sophisticated were these strategies
and tools need to become? What role will continuous
innovation, new analytical methods, maybe even
AI, play in ensuring drug quality and safety
in the future? It's a field that's constantly
moving, constantly adapting to protect public
health.